Want to see AU:IMR full AI Analyst Report?
Top Page
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
(Sydney:IMR)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$1.00
▼(-47.92% Downside)
Action:Downgraded
Date:10/03/26
The score is weighed down primarily by very weak financial performance (tiny and declining revenue, negative gross profit, large losses, and persistent cash burn) alongside elevated leverage. Technicals add further pressure with a clear downtrend and negative momentum. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Specialized MRI-guided electrophysiology platform
A focused MRI-guided electrophysiology platform gives Imricor a clearly defined position in a specialized medical-device niche. Its products are designed around a distinct clinical workflow, which can support durable differentiation as hospitals adopt MRI-enabled cardiac procedures.
Negative Factors
Very small and declining revenue with negative gross profit
Extremely low and shrinking revenue indicates that commercial scale has not yet been established, while recurring negative gross profit shows products are not currently covering direct costs. This limits operating leverage and makes sustained profitability dependent on substantial future growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized MRI-guided electrophysiology platform
A focused MRI-guided electrophysiology platform gives Imricor a clearly defined position in a specialized medical-device niche. Its products are designed around a distinct clinical workflow, which can support durable differentiation as hospitals adopt MRI-enabled cardiac procedures.
Read all positive factors
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$480.49M
Dividend YieldN/A
Average Volume (3M)1.19M
Price to Earnings (P/E)―
Beta (1Y)1.89
Revenue Growth-68.64%
EPS Growth36.40%
CountryAU
Employees78
SectorGeneral
Sector StrengthN/A
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-0.11
Shares Outstanding358,650,630
10 Day Avg. Volume1,127,983
30 Day Avg. Volume1,186,432
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)27.34
Price to Sales (P/S)1042.05
P/FCF Ratio-15.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.10Price Target Upside61.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.1
Revenue Forecast (FY)AU$2.30M
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Business Overview & Revenue Model
Company Description
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East....
How the Company Makes Money
Imricor makes money primarily by selling medical devices used in electrophysiology procedures—specifically MRI-compatible ablation and diagnostic catheter products and associated components required to perform procedures in an MRI suite. Revenue i...
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 121.83K | 302.50K | 959.42K | 615.57K | 816.01K | 696.27K |
| Gross Profit | -2.81M | -2.10M | -924.12K | -1.12M | -1.53M | -1.90M |
| EBITDA | -26.64M | -22.56M | -15.35M | -21.72M | -16.47M | -19.57M |
| Net Income | -37.54M | -26.20M | -29.69M | -22.63M | -17.53M | -20.56M |
Balance Sheet | ||||||
| Total Assets | 73.59M | 45.79M | 21.62M | 8.31M | 13.70M | 26.86M |
| Cash, Cash Equivalents and Short-Term Investments | 67.46M | 40.81M | 15.71M | 831.52K | 5.69M | 18.52M |
| Total Debt | 34.02M | 25.97M | 21.35M | 10.42M | 4.45M | 1.74M |
| Total Liabilities | 44.52M | 34.26M | 29.00M | 17.06M | 6.19M | 4.46M |
| Stockholders Equity | 29.07M | 11.53M | -7.38M | -12.83M | 7.51M | 22.40M |
Cash Flow | ||||||
| Free Cash Flow | -24.67M | -20.20M | -15.65M | -13.06M | -17.06M | -18.11M |
| Operating Cash Flow | -23.87M | -19.75M | -15.57M | -12.98M | -16.82M | -17.49M |
| Investing Cash Flow | -8.11M | -22.47M | -74.98K | -82.78K | -238.86K | -695.30K |
| Financing Cash Flow | 40.39M | 44.55M | 30.33M | 8.21M | 3.94M | 11.59M |
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Technical Analysis
Negative
1.92
Price Trends
1.68
Negative
1.77
Negative
1.85
Negative
Market Momentum
-0.10
Negative
30.08
Neutral
14.73
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMR, the sentiment is Negative. The current price of 1.92 is above the 20-day moving average (MA) of 1.42, above the 50-day MA of 1.68, and above the 200-day MA of 1.85, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 30.08 is Neutral, neither overbought nor oversold. The STOCH value of 14.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IMR.
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | AU$139.43M | -16.54 | -46.84% | ― | ― | 20.40% | |
45 Neutral | AU$14.66M | -0.39 | -259.31% | ― | 14.85% | -1.74% | |
43 Neutral | AU$29.36M | -2.73 | -188.06% | ― | 15.58% | 37.17% | |
41 Neutral | AU$41.71M | -11.86 | -198.77% | ― | -52.35% | 40.38% | |
41 Neutral | AU$46.52M | -2.38 | -62.14% | 0.64% | 12.05% | -31.71% | |
40 Underperform | AU$480.49M | -8.00 | -184.93% | ― | -68.64% | 36.40% |
* General Sector Average
AU:IMR
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
1.34
-0.07
-4.96%
AU:IPD
Impedimed Limited
0.01
-0.03
-69.57%
AU:HMD
HeraMED Ltd.
0.04
<0.01
5.88%
AU:CYC
Cyclopharm Limited
0.37
-0.27
-42.19%
AU:MX1
Micro-X Ltd.
0.04
-0.06
-61.00%
AU:EMV
EMvision Medical Devices Ltd.
1.50
-0.26
-14.77%
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Corporate Events
Imricor Medical Systems Options Lapse Trims Potential Share Dilution
Oct 12, 2026
Imricor Medical Systems Inc., an ASX-listed medical technology firm, reported a change in its issued capital structure following the lapse of certain conditional securities. The company, which operates in the healthcare technology sector, continue...
Imricor Clears Major FDA Hurdle on MR-Guided Ablation Platform
Oct 7, 2026
Imricor Medical Systems, Inc. operates in the medical devices sector, specialising in MR-compatible equipment for interventional cardiac procedures under real-time magnetic resonance guidance rather than x-ray fluoroscopy. Its portfolio spans capi...
Imricor issues new shares and CDIs, confirms compliance and restrictions
Sep 17, 2026
Imricor Medical Systems has issued 78,125 Class A common shares at US$0.60 each upon the exercise of existing warrants and corresponding CHESS Depositary Interests, with the new securities ranking equally with its existing CDIs and shares. The com...
Imricor Clears Major FDA Milestone as Manufacturing Module Wins PMA Acceptance
Sep 2, 2026
Imricor Medical Systems, Inc. announced that the U.S. Food and Drug Administration has completed its evaluation of the manufacturing module within the company’s modular Premarket Approval submission and formally accepted and closed it. The m...
Imricor and Philips debut commercial MR-guided cardiac lab solution
Aug 27, 2026
Imricor Medical Systems has launched a commercial interventional MR lab solution in collaboration with Royal Philips, combining Philips’ 1.5T BlueSeal helium-free MRI platform and workflow capabilities with Imricor’s NorthStar, Advanta...
Imricor Adds Children’s Medical Center Dallas as Second U.S. NorthStar Customer
Aug 9, 2026
Imricor Medical Systems has secured Children’s Medical Center Dallas as its second U.S. hospital customer for the NorthStar interventional magnetic resonance mapping and guidance system, just two weeks after its domestic commercial launch. T...
Imricor outlines regulatory framework and limits of new 1H 2026 investor briefing
Aug 9, 2026
Imricor Medical Systems has released a 1H 2026 investor presentation outlining general background information on the company, its activities, and its securities on the ASX. The document emphasises that the materials are a high-level summary, rely ...
Imricor Files Q2 2026 10-Q, Confirms Status as Emerging Growth Medical Tech Company
Aug 9, 2026
Imricor Medical Systems, Inc. has filed its quarterly report on Form 10-Q for the period ended June 30, 2026, confirming it remains a non-accelerated, smaller reporting, emerging growth company under U.S. securities regulations. The company report...
Imricor accelerates U.S. MR-guided cardiac launch with Rady Children’s and fresh capital
Aug 9, 2026
Imricor has formally entered the U.S. market, launching its Imricor Cardiovascular business line and securing Rady Children’s Hospital–San Diego as its first American customer for the NorthStar-guided, radiation-free cardiac catheteris...
Imricor Gains Philips Compatibility, Expands iMR Footprint Ahead of ESC Congress
Aug 6, 2026
Imricor Medical Systems has secured a Third Party Product Compatibility Declaration from Philips Medical Systems covering its interventional MR products for use with specified Philips MR systems and upgrades running R12.1.1 or later. The certifica...
Imricor sets date for Q2 FY26 results and investor webinar
Aug 3, 2026
Imricor Medical Systems will release its financial results for the quarter ended 30 June 2026 on 10 August 2026 and will host an investor webinar the same morning, led by Chair and CEO Steve Wedan and CFO Jonathon Gut. The event underscores the co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.